japanese%20encephalitis%20virus
JAPANESE ENCEPHALITIS VIRUS

Japanese encephalitis virus is an RNA flavivirus that causes virus encephalitis across Asia, the western Pacific region and parts of Australia.

It is transmitted in an enzootic cycle and the virus is transmitted to humans through the bite of infected Culex tritaeniorhynchus mosquitoes.

There is no specific antiviral treatment for Japanese encephalitis virus and management is mainly symptomatic treatment and supportive care.

Personal protection from mosquito bites in endemic areas and obtaining vaccination are the primary strategies to control Japanese encephalitis virus infection due to lack of specific antiviral therapy, high case fatality, and substantial morbidity.

Japanese%20encephalitis%20virus Treatment

Supportive Therapy

  • Mode of therapy for Japanese encephalitis virus infection are symptomatic treatment, supportive care and management of complications
  • There is no specific antiviral treatment for Japanese encephalitis virus infection
  • Hospitalization for supportive care and close observation is generally required
  • Careful nursing care and physiotherapy are needed to reduce the risk of bed sores, malnutrition and contractures
  • Rest, fluids and pain relievers are used to reduce fever and relieve some symptoms
  • In controlled clinical trials, corticosteroids, Interferon alpha-2a or Ribavirin did not improve clinical outcome
  • Supportive care for Japanese encephalitis patients should be emphasized on:
    • Control of intracranial pressure
    • Maintenance of adequate cerebral perfusion pressure
    • Seizure control
    • Prevention of secondary complications
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.